Last reviewed · How we verify

Intraperitoneal and port sites infiltration

medina medical center · Phase 1 active Small molecule

Intraperitoneal and port sites infiltration is a Small molecule drug developed by medina medical center. It is currently in Phase 1 development.

At a glance

Generic nameIntraperitoneal and port sites infiltration
Sponsormedina medical center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intraperitoneal and port sites infiltration

What is Intraperitoneal and port sites infiltration?

Intraperitoneal and port sites infiltration is a Small molecule drug developed by medina medical center.

Who makes Intraperitoneal and port sites infiltration?

Intraperitoneal and port sites infiltration is developed by medina medical center (see full medina medical center pipeline at /company/medina-medical-center).

What development phase is Intraperitoneal and port sites infiltration in?

Intraperitoneal and port sites infiltration is in Phase 1.

Related